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Abstract
Objective: To compare the effects of antiplatelets and anticoagulants on stroke and death in patients with acute cervical
artery dissection.
Design: Systematic review with Bayesian meta-analysis.
Data Sources: The reviewers searched MEDLINE and EMBASE from inception to November 2012, checked reference lists,
and contacted authors.
Study Selection: Studies were eligible if they were randomised, quasi-randomised or observational comparisons of
antiplatelets and anticoagulants in patients with cervical artery dissection.
Data Extraction: Data were extracted by one reviewer and checked by another. Bayesian techniques were used to
appropriately account for studies with scarce event data and imbalances in the size of comparison groups.
Data Synthesis: Thirty-seven studies (1991 patients) were included. We found no randomised trial. The primary analysis
revealed a large treatment effect in favour of antiplatelets for preventing the primary composite outcome of ischaemic
stroke, intracranial haemorrhage or death within the first 3 months after treatment initiation (relative risk 0.32, 95%
credibility interval 0.12 to 0.63), while the degree of between-study heterogeneity was moderate (t2 = 0.18). In an analysis
restricted to studies of higher methodological quality, the possible advantage of antiplatelets over anticoagulants was less
obvious than in the main analysis (relative risk 0.73, 95% credibility interval 0.17 to 2.30).
Conclusion: In view of these results and the safety advantages, easier usage and lower cost of antiplatelets, we conclude
that antiplatelets should be given precedence over anticoagulants as a first line treatment in patients with cervical artery
dissection unless results of an adequately powered randomised trial suggest the opposite.
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Introduction
Dissections of cervical carotid or vertebral arteries are among
the most frequent causes of ischaemic stroke in young adults
according to hospital-based series [1–3]. More than a quarter of
patients with stroke caused by cervical artery dissection develop
relevant disability, while almost half report a decreased quality of
life [4]. The socio-economic consequences are significant, because
patients with cervical artery dissection are on average 45 years of
age and play an important role in private, business and social life
[5]. Brain imaging studies and detection of micro-embolic signals
by transcranial ultrasound in patients with cervical artery
dissection suggest that arterial embolism is the main mechanism
of stroke [6,7]. Most physicians prescribe anticoagulants for stroke
prevention in patients with acute cervical artery dissection,
although no randomised trial has compared the safety and efficacy
of anticoagulants with antiplatelets or placebo. In addition, the
International Stroke Trial has shown that the potential benefit of
anticoagulants is offset by an increased risk of intracranial
haemorrhage in patients with acute ischaemic stroke [8].
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Hitherto, three meta-analyses comparing antiplatets and
anticoagulants in patients with cervical artery dissection were
published [9–11]. All three used frequentist methods for statistical
analysis. Summary estimates, uncertainty, and statistical signifi-
cance vary depending on the analytical approach used. In the
presence of many studies with scarce or zero events in either or
both groups and imbalances in the size of comparison groups, the
statistical analysis becomes challenging [12,13]. This is the case for
many of the studies comparing antiplatelets and anticoagulants in
patients with cervical artery dissection. The original Cochrane
Review and its recent update excluded studies with zero events in
both groups [9,11]. This approach may have biased results in
either direction, particularly in view of the considerable imbal-
ances in group sizes. Menon and colleagues included studies with
zero events in both groups [10], but the analytical technique used
gave undue weight to studies with zero events in both groups and
is therefore likely to have biased results towards underestimating
potential differences in the effects of antiplatelets and anticoagu-
lants. Therefore, we conducted a systematic review and meta-
analysis using appropriate Bayesian techniques to account for
studies with scarce event data. We compared the effects of
antiplatelets and anticoagulants on the composite of ischaemic
stroke, intracranial haemorrhage or death as primary outcome,
and determined whether estimated treatment effects differed
according to the site of dissection or methodological quality of
included studies.
Methods
Data Sources and Searches
We searched MEDLINE and EMBASE (from inception to
November 2012) using a combination of keywords, text words,
and specific database terms related to carotid and vertebral artery
dissection and to interventions (see Appendix S1). Search strategies
were developed by an experienced medical librarian in collabo-
ration with neurologists experienced in the field of interest (HS,
RWB). We used similar strategies to identify previously published
systematic reviews and meta-analysis, searched clinical trial
registries, screened reference lists of all retrieved reports and
contacted experts in the field. There were no restrictions regarding
language or publication status. See Appendix S2 for the review
protocol.
Study Selection
We included any randomised, quasi-randomised or observa-
tional study that allowed a within-study comparison of antiplatelets
and anticoagulants administered for an intended duration of at
least 3 months in patients with cervical artery dissection. Patients
with intended shorter durations of treatment or with treatment
regimens including a switch from one treatment to the other
before 3 months were excluded, as were patients who underwent a
surgical intervention of the dissected artery, patients with
traumatic or isolated intracranial dissections, and children.
Therefore, patient numbers reported here will not necessarily
correspond to those previously published. Dissections were
considered to be of traumatic origin in the presence of severe
blunt head or neck traumas, occuring most often due to motor
vehicle accidents [14,15]. Conversely, dissections associated with
minor trauma (e.g. sneezing, coughing, vomiting, minor injuries
after sport or recreational activities) were considered spontaneous
and included [16,17]. Studies which did not provide 3 month
follow-up data were excluded, as were case series in patients only
treated with one of the interventions. Eligibility of all reports was
determined by one reviewer (HS) and independently checked by
one out of three other reviewers (RWB, BdC, or PJ).
Outcome Measures
The primary outcome was the composite of ischaemic stroke,
symptomatic intracranial haemorrhage or death occurring up to
three months after initiation of antithrombotic treatment.
Secondary outcomes were the composite of ischaemic stroke or
symptomatic intracranial haemorrhage; ischaemic stroke; symp-
tomatic intracranial haemorrhage; transient ischaemic attack;
death; and the composite of ischaemic stroke or transient
ischaemic attack. If three-month follow-up data were not available
in published reports, we requested these data from authors.
Data Extraction and Quality Assessment
Data on clinical outcomes and methodological quality were
extracted by one reviewer (HS) and checked by another (BdC). We
contacted the corresponding authors if additional information on
outcome data was required for the specified follow-up period, or
for the eligible patient population, overall or stratified by site of
dissection (carotid or vertebral). The following components of
methodological quality that may be associated with bias in
therapeutic research were assessed: prospective design; enrolment
of consecutive patients with cervical artery dissection; blinding of
investigators responsible for the adjudication of clinical events; and
inclusion of all enrolled patients in the analysis (in analogy to the
intention-to-treat principle used in randomised trials). In addition,
we classified studies according to their size and according to
balance in the size of treatment groups. Studies were considered
have balanced sizes of treatment groups if the difference in the
number of patients between groups was less than fourfold. For
example, a study had included 83 patients receiving aspirin and 47
receiving anticoagulants and was considered to be balanced [18].
Conversely, another study had included 9 patients receiving
aspirin and 113 receiving anticoagulants and was deemed to have
unbalanced sizes of treatment groups [19]. Studies were consid-
ered large if they had included more than 15 patients in each
treatment group, and more than 50 patients overall. Disagree-
ments were resolved by consensus.
Statistical Analysis
We used a Bayesian method developed for random effects meta-
analysis on the relative risk scale [20,21]. The model adequately
accounts for situations with sparse event data, including zero cells
in one or both treatment groups. Monte-Carlo Markov Chain
simulation methods were used to obtain posterior distributions of
the relative risks (RRs) of outcomes of interest and of t2. Pooled
RRs were estimated from the median of the respective posterior
distributions [21]. An RR below one indicates a benefit of
antiplatelets as compared with anticoagulants. 95% credibility
intervals (95% CrI) were obtained from the 2.5th and the 97.5th
percentile of the posterior distribution, which can be interpreted
similarly to a conventional 95% confidence interval. Between-
study heterogeneity was considered low if the median of the
posterior distribution of t2 was 0.04 or less; t2 estimates of 0.14
may be interpreted as a moderate and 0.40 as a high degree of
heterogeneity between studies [22,23]. Analyses were performed
overall in all patients, and stratified according to site of dissection
(carotid or vertebral). For three outcomes, we observed high
degrees of heterogeneity; we identified the study contributing most
to between-study heterogeneity and repeated the analyses after
exclusion of this study.
For the primary composite outcome, we performed analyses of
the overall population stratified by the following pre-specified
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methodological criteria: prospective design; enrolment of consecu-
tive patients; inclusion of all enrolled patients in the analysis; study
size; and balanced size of treatment groups. We also stratified the
analysis of the primary composite outcome according to two post
hoc classifications according to methodological quality: studies that
satisfied all five of the above criteria (prospective design, consecutive
patients, inclusion of all patients in the analysis, balanced group size
and large sample size overall) versus studies that did not; studies, for
which we were able to reconfirm with authors that outcome data
included in our analysis were complete, versus studies for which this
was not the case. All stratified analyseswere accompanied by tests for
interaction between study characteristic and treatment effect. Then,
we performed a post hoc analysis of all outcomes restricted to studies
that satisfied all five pre-specified methodological criteria [24]. After
the publication of the International Stroke Trial in 1997, patients
with severe stroke were more likely to receive antiplatelets than
anticoagulants due to the lower risk of intracranial haemorrhage [8].
We therefore determined whether there was evidence for con-
founding by indication by stratifying the analysis of overall mortality
according to time-point of death (#7 days versus .7 days after
symptoms onset). Finally, we re-analysed the two previous meta-
analyses [10,11] using our Bayesian random-effects model. Then,
we compared results from intersecting studies, which were included
in our meta-analysis as well as in those previously published, with
results from studies only included in our meta-analysis, and studies
only included in the previously published meta-analyses, but
excluded from ours. See Appendix S3 for an extended description
of statistical methods. Analyses were done using Stata version 11.0
and WinBUGS version 1.4.3 [25,26].
Results
We identified 4171 unique references through our literature
search and considered 210 for detailed evaluation (Figure 1).
Thirty-seven studies performed in 1991 patients fulfilled our
eligibility criteria and were included. All were published as full-text
articles. The median year of publication was 1998 (range, 1978 to
2012). All 37 studies were observational, allowing a comparison of
antiplatelets with anticoagulants [18,19,27–61]. No randomised
trial was identified. The median number of patients per study was
21 (range, 2 to 315), with 527 (26%) patients receiving antiplatelets
and 1464 (74%) receiving anticoagulants. Twenty-four studies
reported outcomes for 1039 patients with internal carotid artery
dissection [18,27–33,35,37–40,45,47,49–51,54–58,60]. Fifteen
Figure 1. Study flow diagram.
doi:10.1371/journal.pone.0072697.g001
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studies reported outcomes for 532 patients with vertebral artery
dissection [18,34,36,42–44,46,49–52,54,55,58,59]. Two studies
(223 patients) had included patients with internal carotid or
vertebral dissection, but clinical outcomes stratified according to
site of dissection were unavailable [19,48]. Table 1 presents the
methodological characteristics of included studies. Prospective
design was reported in 10 studies (27%) including 874 patients
[18,44,45,48,50,52,53,57,59,61], and recruitment of consecutive
patients in 19 studies (51%) with 1673 patients
[18,19,31,32,34,44–50,52–55,57–59]. Nineteen studies (51%) with
a total of 1029 patients included all eligible patients in the analysis
[18,19,27,29,30,37,38,40–42,45,47,48,50,53,56,57,59,60]. Twen-
ty-nine studies (78%) including 1125 patients satisfied our criteria
of balanced group sizes [18,27–31,33,35–48,50,52–57,61], and
eight studies including 1146 patients were considered large
[18,40,48,49,52,53,57,61]. Four studies (11%) in 631 patients
satisfied all 5 criteria and were considered to be of higher
methodological quality overall [18,48,53,57]. None of the included
studies reported blinding of investigators responsible for the
adjudication of clinical events. For 16 studies, we were able to
reconfirm with investigators that outcome data included in our
analysis were complete [18,19,37,44,47,49–55,57–60].
Table 2 presents the clinical outcomes of all included studies.
Thirty-six studies contributed to the analysis of the primary
composite outcome of ischaemic stroke, intracranial haemorrhage
or death [18,19,27–60]. Sixty-one patients experienced the
primary composite outcome, 13 of 467 patients with antiplatelets
and 48 of 1416 patients with anticoagulants. Figure 2 (top)
indicates an advantage of antiplatelets over anticoagulants, with a
68% reduction in the relative risk of ischaemic stroke, intracranial
haemorrhage or death afforded by antiplatelets (RR 0.32, 95%
CrI 0.12 to 0.63). A t2 of 0.18 indicated a moderate degree of
between-study heterogeneity.
Thirty-seven studies in 527 patients with antiplatelets and 1464
patients with anticoagulants contributed to the analysis of the
ischaemic stroke and death (Table 2) [18,19,27–61]. Six patients
with antiplatelets and 24 patients with anticoagulants experienced
an ischaemic stroke. The pooled relative risk was 0.29 (95% CrI
0.08 to 0.77) and a t2 of 0.13 indicated a moderate heterogeneity
between studies (Figure 2). Eight patients with antiplatelets and 15
patients with anticoagulants died during the follow-up of 3 months
(pooled RR 0.69, 95% CrI 0.23 to 1.99), with a moderate
heterogeneity between studies (t2 = 0.18, Figure 2). The pooled
RR was higher for deaths occurring within 7 days of treatment
initiation (RR 1.20, 95% CrI 0.30 to 4.41) than for death
occurring thereafter (RR 0.19, 95% 0.01 to 152), but a test for
interaction between time of death and estimated RR did not
provide strong evidence for the presence of interaction (p for
interaction = 0.14).
Thirty-six studies in 468 patients with antiplatelets and 1436
patients with anticoagulants contributed to the analyses of
intracranial haemorrhage and the composite of ischaemic stroke
and intracranial haemorrhage [18,19,27–60]. Intracranial haem-
orrhages occurred in none of the patients with antiplatelets, but in
10 patients with anticoagulants. Accordingly, the pooled RR was
estimated at 0.00 (95% CrI 0.00 to 0.05), and a t2 of 0.18
indicated a moderate statistical heterogeneity (Figure 2). Five
patients with antiplatelets and 33 patients with anticoagulants
experienced the composite of ischaemic stroke or intracranial
haemorrhage. The pooled RR was 0.15 (95% CrI 0.04 to 0.41)
and the heterogeneity between studies moderate (t2 = 0.22,
Figure 2).
Thirty-six studies in 445 patients with antiplatelets and 1416
patients with anticoagulants contributed to the analysis of transient
ischaemic attack and the composite of ischaemic stroke or
transient ischaemic attack [19,27–61]. Eighteen patients with
antiplatelets and 29 patients with anticoagulants experienced a
transient ischaemic attack and there was little evidence for a
difference between groups (RR 1.06, 95% CrI 0.32 to 2.92), but a
high degree of heterogeneity between studies (t2 = 1.62, Figure 2).
Twenty-one patients with antiplatelets and 50 patients with
anticoagulants experienced the composite of ischaemic stroke or
transient ischaemic attack. The pooled RR was 0.59 (95% CrI
0.19 to 1.45), but the heterogeneity between studies was large
(t2 = 1.74).
Thirty-five studies in 386 patients with antiplatelets and 1388
patients with anticoagulants contributed to the analysis of the
composite outcome of ischaemic stroke, intracranial haemorrhage
or transient ischaemic attack.) [19,27–60]. Seventeen patients with
antiplatelets and 59 patients with anticoagulants experienced the
composite of ischaemic stroke, intracranial haemorrhage or
transient ischaemic attack. The pooled RR was 0.34 (95% CrI
0.10 to 0.88) and a t2 of 2.03 again indicated large statistical
heterogeneity.
Figure 3 presents results of analyses stratified according to site of
dissection. Estimates varied to some extent according to dissection
site, but tests for interaction were negative for 7 out of the 8
outcomes, including the primary composite of ischaemic stroke,
intracranial haemorrhage or death. The test for interaction
between site of dissection and estimated treatment effect was
positive, however, for ischaemic stroke (p for interaction = 0.02),
suggesting a more pronounced benefit of antiplatelets in patients
with vertebral dissection.
Table 3 presents results from analyses of the primary outcome
stratified according to study characteristics. Throughout, estimat-
ed relative risks were nearer 1 in studies that satisfied a
methodological criterion. Tests for interaction between estimated
relative risks and methodological criteria formally reached
statistical significance for prospective study design (p for interac-
tion = 0.01) and balanced group size (p for interaction = 0.04),
and a statistical trend for consecutive recruitment of patients (p for
interaction = 0.06).
Table 4 shows results from a post hoc analysis of all outcomes
restricted to studies that satisfied all five pre-specified methodo-
logical criteria. Compared with the analysis of all studies, estimates
became less beneficial for antiplatelets on all outcomes except
transient ischaemic attack. 95% CrI all overlapped the null effect
at a RR of 1 for all outcomes, except intracranial haemorrhage.
Studies that satisfied all five pre-specified methodological criteria
showed a pooled RR of 0.73 (95% CrI 0.17 to 2.30), studies that
satisfied four criteria or less showed a pooled RR of 0.20 (95% CrI
0.06 to 0.47; p for interaction = 0.07). For the 16 studies, for
which we were able to reconfirm with investigators that outcome
data included in our analysis were complete we found a pooled
RR of 0.40 (95% CrI 0.12 to 0.91), in remaining studies a pooled
RR of 0.17 (95% CrI 0.02 to 0.60; p for interaction 0.17).
Table 5 shows a comparison of results of our and previous meta-
analyses [10,11]. Engelter and Lyrer used a fixed-effect model to
derive pooled Peto odds ratios. They found clinically relevant, but
non-significant reductions in the odds of stroke (OR 0.63, 95% CI
0.21 to 1.86) and intracranial haemorrhage (OR 0.25, 95% CI
0.02 to 3.36), but a clinically relevant trend towards higher overall
mortality associated with antiplatelets as compared with antico-
agulants (OR 2.02, 95% CI 0.62 to 6.60). Our re-analysis of
Engelter and Lyrer’s data using our Bayesian random-effects
model (Table 5, top) shows a pronounced, albeit non-significant
55% relative reduction of stroke and a pronounced, statistically
significant 100% relative risk reduction of intracranial haemor-
Antithrombotics and Cervical Artery Dissection
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rhage. The 40% relative risk increase of death was non-significant
and less pronounced than reported by Engelter and Lyrer [11]
.The 20 intersecting studies in 1109 patients included in their and
in our meta-analysis were less beneficial for antiplatelets (RR of
stroke 0.64, 95% CrI 0.18 to 2.14) than the 16 studies in 176
patients included only in their meta-analysis (RR 0.45, 95% CrI
0.15 to 1.41) and the 17 studies in 882 patients included only in
our meta-analysis (RR 0.19, 95% CrI 0.02 to 0.97, Table 5,
middle). Menon et al used a fixed-effect model, which was not
further specified. They found a small risk difference of 20.01 for
stroke (95% CI 20.06 to 0.04), which was slightly in favour of
antiplatelets, and a more pronounced risk difference in opposite
direction of 0.05 in favour of anticoagulants for the composite of
stroke or TIA (95% CI 20.01 to 0.11). In our re-analysis of their
data (Table 5, top), we also found opposite directions of effects.
However, on a relative risk scale, these opposite effects had the
same magnitude: a 49% relative risk reduction for stroke and a
48% relative risk increase for the composite of stroke or TIA
associated with antiplatelets, with considerable imprecision of both
estimates, as evidenced by wide 95% credibility intervals. The 18
intersecting studies in 553 patients included in their and our meta-
analysis (RR of stroke 0.48, 95% CrI 0.10 to 1.76) and the 16
Table 1. Characteristics of identified studies.
Study, Year
(Reference)
Study
Population Prospective Consecutive
No
exclusions*
Balanced
group size Large
Fisher et al. 1978 [27] carotid no unclear yes yes no
Luken et al. 1979 [28] carotid unclear unclear no yes no
Sellier et al. 1983 [29] carotid unclear unclear yes yes no
Vanneste et al. 1984 [30] carotid no no yes yes no
Mokri et al. 1986 [31] carotid no yes no yes no
Bogousslavsky et al. 1987 [32] carotid unclear yes no no no
Marx et al. 1987 [33] carotid unclear unclear no yes no
Mas et al. 1987 [34] vertebral unclear yes no no no
Landre et al. 1987 [35] carotid no no no yes no
Mokri et al. 1988 [36] vertebral unclear unclear no yes no
De Bray et al. 1989 [37] carotid unclear unclear yes yes no
Eljamel et al. 1990 [38] carotid unclear unclear yes yes no
Schievink et al. 1990 [39] both unclear unclear no yes no
Ast et al. 1993 [40] carotid no unclear yes yes yes
Landini et al. 1996 [41] both unclear unclear yes yes no
Pego et al. 1996 [42] vertebral no unclear yes yes no
Plaza et al. 1996 [43] vertebral unclear unclear no yes no
De Bray et al. 1997 [44] vertebral yes yes no yes no
Biousse et al. 1998 [45] carotid yes yes yes yes no
Han et al. 1998 [46] vertebral no yes no yes no
Engelter et al. 2000 [47] carotid no yes yes yes no
Beletsky et al. 2003 [48] both yes yes yes yes yes
Dziewas et al. 2003 [19] both no yes yes no no
Touze´ et al. 2003 [49] both no yes no no yes
Caso et al. 2004 [51] both no yes yes yes no
Campos et al. 2004 [50] both yes unclear no no no
Arauz et al. 2006 [18] both yes yes yes yes yes
Arnold et al. 2006 [52] vertebral yes yes no yes yes
De Bray et al. 2007 [53] both yes yes yes yes yes
Nyberg et al. 2007 [54] both no yes no yes no
Simoes et al. 2007 [55] both no yes no yes no
Rigamonti et al. 2008 [56] carotid no no Yes yes no
Georgiadis et al. 2009 [57] carotid yes yes yes yes yes
Metso et al. 2009 [58] both no yes no no no
Arauz et al. 2010 [59] vertebral yes yes yes no no
Divjak et al. 2011 60 carotid no no yes no no
Kennedy et al. 2012 61 both no no yes yes yes
*No exclusions refers to no exclusions of eligible patients from the analysis.
doi:10.1371/journal.pone.0072697.t001
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studies in 209 patients included only in their meta-analysis (RR
0.65, 95% CrI 0.02 to 13.72) were less beneficial for antiplatelets
than the 19 studies in 1438 patients included only in our meta-
analysis (0.15, 95% CrI 0.02 to 0.70, Table 5, bottom).
Sensitivity analyses using different statisticalmethods are reported
in Appendix S4. For the primary composite endpoint of stroke,
intracranial haemorrhage or death, we found point estimates and
precision much the same for all five methods used. This was also the
case for stroke, death, and the composite of stroke or intracranial
haemorrhage. For remaining outcomes, there were some differences
in point estimates or precision, but overlapping credibility intervals
suggested compatibility of estimates.
Discussion
In this meta-analysis of 37 observational studies comparing
antiplatelets with anticoagulants in 1991 patients with cervical
artery dissection, we found evidence to suggest a clinically relevant
advantage of antiplatelets over anticoagulants on the primary
outcome (composite of ischaemic stroke, intracranial haemorrhage
or death), and 4 out of 7 secondary outcomes. When we stratified
according to components of study quality, we found the benefit of
antiplatelets considerably less pronounced in studies of higher
methodological quality. Tests for interaction between estimated
relative risks and study characteristics formally reached statistical
significance for prospective study design and balanced group size,
and showed a statistical trend for consecutive recruitment of
patients and analysis in accordance with the intention-to-treat
principle. In an analysis restricted to studies, which satisfied all
pre-specified methodological criteria, credibility intervals were
wide for all outcomes, except for intracranial haemorrhage, and
were compatible with both, a substantial advantage or disadvan-
tage of antiplatelets over anticoagulants. Furthermore, we
stratified analyses according to the site of dissection, i.e. carotid
or vertebral artery. This analysis showed similar results in the two
groups, even though tests for interaction between the site of
dissection and the estimated treatment effect were positive for
ischaemic stroke and the composite of ischaemic stroke or
intracranial haemorrhage. None of the numerous analyses
provided robust evidence that anticoagulants are more beneficial
than antiplatelets in patients with cervical artery dissection. The
risk of intracranial hemorrhage was lower in the antiplatelet group
and may be considered to contradict contemporary trials, which
found aspirin in patients with atrial fibrillation not safer than
warfarin [62,63]. This apparent contradiction may be explained
by the characteristics of included patients (age, comorbidity and
severity of stroke) and timing of treatment initiation (immediate
versus delayed): patients with cervical artery dissection are
typically younger and have less comorbid conditions than patients
with atrial fibrillation at risk of stroke considered for antiplatelet
treatment, but typically experience severe strokes with large brain
tissue infarction. If treatment is initiated immediately, these
patients may be more likely to suffer intracranial haemorrhage
with anticoagulation as compared to antiplatelet treatment [8].
This notion is in accordance with current guidelines, which
recommend against full-dose anticoagulation in patients with acute
ischaemic stroke [64,65].
In our view, the major strength of this study is the use of
Bayesian techniques to address the challenge of studies with scarce
event data and studies with imbalanced sizes of treatment groups
[21]. The major limitation is the complete lack of randomised
trials comparing antiplatelets and anticoagulants in patients with
cervical dissection and the variation in methodological quality of
the observational studies included. We addressed this by perform-
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Figure 2. Pooled relative risks of primary and secondary outcomes comparing antiplatelets with anticoagulants.* Primary endpoint.
ICH = intracranial haemorrhage; TIA = transient ischaemic attack.
doi:10.1371/journal.pone.0072697.g002
Figure 3. Analyses stratified according to site of dissection.* Primary endpoint. ICH = intracranial haemorrhage; TIA = transient ischaemic
attack.
doi:10.1371/journal.pone.0072697.g003
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ing analyses stratified according to methodological quality and
found evidence for overestimations of the benefit of antiplatelets in
studies of lower methodological quality. In an analysis restricted to
studies of higher methodological quality, the possible advantage of
antiplatelets over anticoagulants was less obvious than in the main
analysis. Observational studies may be subject to confounding by
indication: patients with extensive stroke at baseline and substan-
tially increased risk of subsequent intracranial haemorrhage may
be more likely to receive antiplatelets than anticoagulants [66,67].
These patients typically have a poor prognosis and may die early
after initiation of antithrombotic treatment. We were unable to
formally compare stroke severity between patients with antiplatelet
and anticoagulant treatment at baseline because of the low quality
of reporting, but attempted to address this indirectly by
performing an additional analysis of mortality data stratified
according to time of death. During the first seven days after
treatment initiation, we found a trend towards more deaths in the
antiplatelet group, whereas a trend into the opposite direction was
observed for the subsequent period up to 3 months. This
observation indeed suggests confounding by indication, which
may have introduced bias against antiplatelets, although a
statistical test for interaction was negative. Conversely, patients
may have been more likely to receive antiplatelets if they had
lower degree stenoses of cerebral arteries or few clinical symptoms
only [57]. This could have biased results in favour of antiplatelets,
but again, the lack of information on baseline characteristics
prevented us from addressing this formally. Results from adjusted
analysis were available only for one study [57], which used the
presence or absence of cerebral ischemic symptoms as covariate.
The adjusted estimate for the composite of ischemic stroke, TIA or
transient monocular blindness or retinal infarction showed a trend
in favour of antiplatelets (OR 0.38, 95% CI 0.08 to 1.67) [57]. An
alternative attempt to address comparability of groups was the
classification of studies according to the balance in the size of
treatment groups. Some might argue that this criterion is not
obviously related to bias. We pre-specified it as a proxy for
pronounced differences in treatment indication in a specific study.
For example, in the study by Dziewas et al, only 7% of patients (9
out of 122) [19] had received antiplatelets as opposed to 64% in
the study by Arauz et al (83 out of 130) [18]. We consider it more
likely in the first than in the second study that pronounced
differences in indication for treatment introduced bias: the 7% of
patients who received antiplatelets are likely to be highly selected
and not comparable with the remaining 93% who received
anticoagulation. We found that this approach towards addressing
comparability of groups was more suitable than a direct
comparison of relevant patient characteristics at baseline between
groups because of the limited quality of reporting of included
studies. A further source of bias is the potential for selective
reporting of outcomes [68] ,which may have biased results in
favour of either treatment. We addressed this in a post hoc
analysis, distinguishing between studies, for which we were able to
reconfirm with authors that outcome data included in our analysis
Table 3. Stratified analyses of the primary outcome according to methodological quality.
Variable
Total
Studies, n
Number of
patients included
RR
(95% CrI) t2*
P Value for
interaction
All studies 37 1991 0.32 (0.1220.63) 0.18
Prospective design 0.13 0.01
Yes 10 874 0.62 (0.2221.47)
No 27 1117 0.05 (0.0020.30)
Consecutive enrolment of patients 0.16 0.06
Yes 19 1673 0.45 (0.1620.98)
No 18 318 0.09 (0.0020.52)
Intention-to-treat analysis 0.13 0.06
Yes 19 1029 0.52 (0.1621.18)
No 18 962 0.15 (0.0320.51)
Balanced size of treatment groups 0.15 0.04
Yes 29 1131 0.35 (0.1320.67)
No 8 860 0.00 (0.0020.55)
Large sample size 0.17 0.08
Yes 8 1146 0.51 (0.1521.31)
No 29 845 0.17 (0.0420.51)
*Note that only one t2 was estimated per outcome.
doi:10.1371/journal.pone.0072697.t003
Table 4. Pooled relative risks of primary and secondary
outcomes found in studies satisfying all 5 methodological
criteria.
Outcome RR (95% CrI) t2
Ischaemic Stroke 0.65 (0.1223.05) 0.15
ICH 0.00 (0.0020.47) 0.18
TIA 0.73 (0.1223.97) 0.18
Death 1.46 (0.17210.79) 0.26
Ischaemic Stroke or ICH 0.52 (0.1022.16) 0.16
Ischaemic Stroke or TIA 0.79 (0.1723.31) 0.19
Ischaemic Stroke, ICH or TIA 0.68 (0.1422.98) 0.21
*Primary endpoint.
ICH = intracranial haemorrhage; TIA = transient ischaemic attack.
doi:10.1371/journal.pone.0072697.t004
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were complete, and studies for which this was not the case. There
was little evidence for a difference in estimated effects, and studies
with complete outcome data showed a robust advantage of
antiplatelets.
We were also unable to address the fact that safety and efficacy
of anticoagulation is associated with control of international
normalized ratio since included studies did not provide the
necessary information [69]. Consequently, we cannot exclude that
patients with appropriate control of their international normalized
ratio will fair better than patients included in our study. Another
limitation may concern the exclusion of patients with a traumatic
dissection, as classification into traumatic or spontaneous form
may be arbitrary in some cases. Furthermore, the state of the
dissected artery (stenosis vs. occlusion), which may be associated
with both, the choice of antithrombotic treatment and prognosis,
was not reported in most studies. Finally, the degree of
heterogeneity between studies observed for three outcomes
(transitory ischaemic attacks, and two composite endpoints
including transitory ischaemic attacks as one of their components)
was high. We identified one study to contribute most to
heterogeneity [19]: it was small, had unbalanced group sizes and
an unusually high rate of transitory ischaemic attacks in patients
treated with antiplatelets. We performed a sensitivity analysis after
exclusion of this study and found heterogeneity decreased, but
emphasise the purely explorative character of this analysis along
with the fact that remaining heterogeneity between studies was still
moderate.
Three meta-analyses have been published so far [9–11]. All
used frequentist methods for statistical analyses. The original
Cochrane Review and its recent update used a fixed effect model
to derive pooled Peto odd ratios excluding studies with zero events
in both groups [9,11,70]. In view of the considerable imbalances in
group sizes, this approach may have introduced bias in favour of
either treatment. The Cochrane Review included only studies
reporting on patients with cervical carotid artery dissection,
whereas we included also patients with vertebral artery dissection.
When analyzing the primary outcome in our study, we found
similar relative risks for carotid (RR 0.14, 95% CrI 0.03 to 0.50)
and vertebral dissections (RR 0.24, 95% CrI 0.04 to 0.97), which
suggests that a combined analysis of the two sites of dissections is
viable. Another important difference is the choice of primary
outcomes, which were overall mortality and the composite of
death or disability in the Cochrane Review [9,11]. For death, they
found a pooled odds ratio of 2.02 (95% confidence interval 0.62 to
6.60), whereas our pooled relative risk was 0.69 (95% CrI 0.23 to
1.99). This difference in pooled estimates may be explained by
chance alone, differences in study selection or differences in the
analytical approaches used. Differences in study selection mainly
occurred because of more stringent selection criteria in our study,
requiring 3-month follow-up data. This follow-up duration was
chosen in view of the frequent change from anticoagulants to
antiplatelets in routine clinical practice that typically occurs after
completion of the first three months of treatment. Other reasons
for differing study selection include a more up to date literature
search and the discussed inclusion of both, patients with carotid
and vertebral dissection, even though we deem it unlikely that
differences in results between the Cochrane Review and our study
can be fully explained by dissection site. Re-analyses of data
included in the Cochrane Review and our meta-analysis reported
in Table 5 in comparison with original results [11] suggested that
the differences between their and our results could be explained by
both, differences in statistical methods and differences in study
identification and selection. We emphasise, however, that widely
overlapping uncertainty intervals indicate that our results for
stroke, intracranial haemorrhage and death are compatible with
both, the Bayesian re-analysis of the data of the Cochrane Review
Table 5. Influence of in- or exclusion of studies on estimated effects.
RR (95% CrI)
Number of
studies
Number of
patients
Ischaemic
Stroke ICH Death
Ischaemic
Stroke or TIA
Our meta-analysis, all included studies 37 1991 0.29 (0.0820.77) 0.00 (0.0020.05) 0.69 (0.2321.99) 0.59 (0.1921.45)
Engelter et al’s meta-analysis,
all included studies
36 1285 0.45 (0.1521.41) 0.00 (0.0020.36) 1.40 (0.4623.79) n/a
Menon et al’s meta-analysis,
all included studies
34 762 0.51 (0.1321.62) n/a n/a 1.48 (0.4124.33)
Engelter et al’s versus our meta-analysis
Studies included in Engelter et al’s
and our meta-analysis
20 1109 0.64 (0.1822.14) 0.00 (0.0020.15) 1.80 (0.3829.15) n/a
Studies included in Engelter et al’s
but not in our meta-analysis
16 176 0.45 (0.1521.41) 0.00 (0.00226.68) 0.96 (0.1324.32) n/a
Studies included in our, but not in
Engelter et al’s meta-analysis
17 882 0.19 (0.0220.97) 0.00 (0.00120.003) 0.33 (0.0321.80) n/a
Menon et al’s versus our meta-analysis
Studies included in Menon et al’s
and our meta-analysis
18 553 0.48 (0.1021.76) n/a n/a 2.00 (0.4427.52)
Studies included in Menon et al’s
but not in our meta-analysis
16 209 0.65 (0.02213.72) n/a n/a 0.76 (0.1024.05)
Studies included in our, but not
in Menon et al’s meta-analysis
19 1438 0.15 (0.0220.70) n/a n/a 0.41 (0.1421.03)
Outcomes included if reported in at least two out of the three available meta-analyses.
ICH = intracranial haemorrhage; TIA = transient ischaemic attack.
doi:10.1371/journal.pone.0072697.t005
Antithrombotics and Cervical Artery Dissection
PLOS ONE | www.plosone.org 10 September 2013 | Volume 8 | Issue 9 | e72697
and the original results published of the Cochrane Review. We did
not analyse the composite of death or disability, since disability
was typically not reported at 3 months, but it is obvious that results
on this long term outcome (odds ratio of 1.77 in favour of
anticoagulants, 95% CI 0.98 to 3.22) reported in Cochrane
Review are in opposition to the majority of our short to midterm
results. This discrepancy could be explained by the different
nature of outcomes, but may also be related to challenges in
interpreting longer term data of included observational studies:
clinical practice frequently involves a switch from anticoagulation
to antiplatelets after 3 to 6 months, thus the true association of
outcomes with type of antithrombotic treatment is difficult to
determine after this period.
Menon and colleagues used a fixed effect model to derive risk
differences and included studies with zero events in both groups
[10]. They observed no relevant difference between antiplatelets
and anticoagulants. This is not surprising because about half of the
studies included had null events in both groups with an estimated
risk difference of zero [10]. Their analytical approach used gave
undue weight to these studies and is likely to have biased results
towards underestimating potential differences [12]. In addition,
they confined the follow-up duration to one month, which will
have led to the exclusion of clinical events and reduced statistical
power as compared with our analysis. Re-analyses of data included
in Menon et al’s and our meta-analysis (reported in Table 5) in
comparison with original results [10] suggested that the differences
can be explained by differences in statistical methods, study
identification and selection, even though the impact of study
identification and selection was more pronounced, with a nearly
threefold increase in the number of patients in our as compared
with Menon et al’s analysis. Studies included either in the
Cochrane Review [11] or in the meta-analysis by Menon et al
[10], which were excluded from our analysis typically because of
short follow-up duration or unclear reporting of type of treatment
or outcome that could be resolved with authors, were small and
had only a small number of primary outcome events.
Currently, two small-scale randomised trials comparing antico-
agulants and antiplatelets in patients with cervical artery dissection
are ongoing. The Cervical Artery Dissection in Stroke Study
(CADISS) aims at including 250 patients. 215 patients have been
randomised by 3rd December 2012 [71]. The other trial, a pilot
study in 20 patients, has completed recruitment [72]. Both trials
are pilot studies, not set up to formally compare antiplatelets with
anticoagulants in terms of patient-relevant clinical outcomes.
Results of our overall analysis suggest an advantage of
antiplatelets over anticoagulants on nearly all outcomes, which
contradict the current preferential use of anticoagulants in routine
clinical practice for patients with cervical artery dissection.
Stratified analyses according to methodological quality showed
less pronounced advantages of antiplatelets in studies of higher
methodological quality, with point estimates nearer the line of no
difference at 1 and credibility intervals compatible with both
relevant advantages and disadvantages of antiplatelets over
anticoagulants. This suggests equipoise between the two types of
treatments and calls for a carefully designed, adequately powered
randomised multicenter trial. A sample size of 2100 patients per
group will provide 80% power at a two-sided alpha of 0.05 to
detect a 30% relative risk reduction in the primary composite
outcome of stroke, intracranial haemorrhage or death from 7% in
patients receiving anticoagulants to 4.9% in patients receiving
antiplatelets. Performing such a trial is difficult, time-consuming
and costly. Cervical artery dissection is a typical example of an
acute rare condition where, globally, it would be possible to recruit
about 4000 patients to conduct a properly powered randomised
trial within one or two years. However, given that each center
would contribute only 1–2 patients per year, literally thousands of
centers would be required, which makes the costs of initiation and
logistics of such a trial prohibitive. Novel approaches might be
needed, with an international trials consortium performing a series
of trials in patients with different types of rare conditions, with
standard procedures, common logistics, and simplified require-
ments for approval by local research ethics committees for the
entire series of trials. For now, considering that discrepancies
between randomised trials and observational studies may be less
pronounced than theoretically expected [73], we call for carefully
conducted prospective cohort studies to fill the evidence gap until
randomised evidence becomes available.
Oral anticoagulants are widely used in routine clinical practice
in patients with cervical artery dissection. They are about 15 times
more expensive than aspirin [74], the classical antiplatelet used in
clinical practice for the treatment of cervical artery dissection,
require a higher degree of compliance, dependent on frequent
laboratory testing and carry a higher risk of intracranial
haemorrhage than antiplatelets. The pharmacokinetic profile of
oral anticoagulants is variable and there are multiple interactions
with drugs and food, which frequently result in poor control of the
INR [75]. As compared to conventional Vitamin K antagonists,
anticoagulation with the novel factor Xa or thrombin inhibitors
were found more effective in stroke prevention in patients with
atrial fibrillation and more practical for handling.76,77 The safety
and effectiveness of these new anticoagulants in patients with
cervical artery dissection will need to be investigated in
randomised trials. Considering these practical and theoretical
disadvantages of anticoagulants and our meta-analysis, which
clearly provides no evidence for a superiority of anticoagulants
over antiplatelets, even pointing towards a harmful effect of
anticoagulants, we question the preferential use of anticoagulants
as a first line treatment in patients with cervical artery dissection
and conclude that antiplatelets should be given precedence
instead, unless results of an adequately powered randomised trial
suggest the opposite.
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